title: Efficacy of Saccharomyces boulardii for treatment of horses with acute enterocolitis.
abstract: OBJECTIVE
  To evaluate the viability of Saccharomyces boulardii after PO administration in clinically normal horses and its efficacy as a treatment for horses with acute enterocolitis.
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  5 clinically normal horses and 14 horses with acute enterocolitis.
  
  
  METHODS
  Feces were collected from 5 clinically normal horses and submitted for microbial culture for 2 days prior to administration of a lyophilized form of S. boulardii (25 or 50 g, PO, q 12 h) for 10 days. Feces were collected for microbial culture 5 and 10 days after treament initiation and 10 days after treatment was discontinued. Fourteen horses with acute enterocolitis were randomly allocated to receive a placebo or S. boulardii (25 g), PO, every 12 hours for 14 days.
  
  
  RESULTS
  S. boulardii was not detected in feces of clinically normal horses. After administration, yeast survived within the gastroinestinal tract but did not permanently colonize it. In horses with acute enterocolitis, the severity and duration of gastrointestinal tract disease during hospitalization were significantly decreased in horses receiving S. boulardii, compared with horses receiving the placebo.
  
  
  CONCLUSIONS
  Administration of S. boulardii may help decrease the severity and duration of clinical signs in horses with acute enterocolitis.
authors.affiliation: Department of Clinical Studies, New Bolton Center campus, University of Pennsylvania, Kennett Square PA 19348, USA.
authors.forename: Anne M
authors.initials: AM
authors.lastname: Desrochers
authors.forename: Brett A
authors.initials: BA
authors.lastname: Dolente
authors.forename: Marie-France
authors.initials: MF
authors.lastname: Roy
authors.forename: Raymond
authors.initials: R
authors.lastname: Boston
authors.forename: Sharon
authors.initials: S
authors.lastname: Carlisle
mesh_terms: D000208:Acute Disease; D000818:Animals; D004760:Enterocolitis / Q000382:microbiology / Q000628:therapy / Q000662:veterinary*; D005243:Feces / Q000382:microbiology; D005260:Female; D006734:Horse Diseases / Q000382:microbiology / Q000628:therapy*; D006736:Horses; D008297:Male; D019936:Probiotics / Q000627:therapeutic use*; D011446:Prospective Studies; D012440:Saccharomyces / Q000502:physiology*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome